SIRIUS – 4.0mm: A Multi-center, non-randomized study of the 4.0 mm CYPHER™ Sirolimus-Eluting Coronary Stent in the Treatment of Patients with DeNovo Native Coronary Artery Lesions
Study of:
CYPHER™ Sirolimus-eluting Coronary 4.0mm stent
The purpose of this study is to assess the safety and effectiveness of the CYPHER™ Sirolimus-eluting Coronary 4.0mm stent in reducing the re-occurrence of coronary narrowings. This stent has been approved by the FDA in smaller sizes (2.5mm, 3.0mm, and 3.5mm). Sirolimus is a potent immunosuppressive agent. We are studying whether the 4.0 mm CYPHER™ stent may slow down the re-occurrence of coronary stenosis (blockage). The results of this study will be compared to stents that are not coated with drug. Patients in this study will have a 6-month follow-up angiogram.
- Ivan J. Chavez, MD, FACC
- Timothy D. Henry, MD, FACC
- John R. Lesser, MD, FACC
- Daniel Lips, MD, FACC
- James D. Madison, MD, FACC
- Michael R. Mooney, MD, FACC
- Wesley R. Pedersen, MD, FACC
- Anil K. Poulose, MD, FACC
- Jay H. Traverse, MD, FACC, FAHA
- Yale Wang, MD, FACC, FSCAI
For more information about this study or the Interventional Cardiology Research program at the Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, please contact Carol Stone at 612-863-9124.
|